Equities research analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.
TherapeuticsMD Trading Down 0.5 %
NASDAQ TXMD opened at $1.88 on Wednesday. TherapeuticsMD has a fifty-two week low of $1.85 and a fifty-two week high of $4.73. The stock has a 50-day simple moving average of $2.21 and a two-hundred day simple moving average of $2.29.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in TherapeuticsMD stock. ADAR1 Capital Management LLC purchased a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned 2.57% of TherapeuticsMD as of its most recent SEC filing. Institutional investors and hedge funds own 30.74% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- What Are Trending Stocks? Trending Stocks Explained
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- The Most Important Warren Buffett Stock for Investors: His Own
- Hilton Demonstrates Asset Light is Right for Investors
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.